Leader of the National Cancer Genomics Consortium, professor Ola Myklebost, and colleagues professors Per Eystein Lønning, Bjørn Tore Gjertsen and Ragnhild A. Lothe point out that in "personalized medicine", cancer patients remain the largest and increasing group that may benefit most from new treatment strategies. The authors emphasize the importance of increase in national clinical trials and participation in high quality international studies for the benefit of the Norwegian cancer patient and to strengthen the Norwegian professional development and research.
BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients
Clin Epigenetics, 14 (1), 115
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Int J Cancer (in press)